(NASDAQ: DXCM) Dexcom's forecast annual revenue growth rate of 11.13% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.23%.
Dexcom's revenue in 2026 is $4,817,900,000.On average, 33 Wall Street analysts forecast DXCM's revenue for 2026 to be $2,056,317,094,433, with the lowest DXCM revenue forecast at $1,955,990,120,413, and the highest DXCM revenue forecast at $2,137,350,419,603. On average, 33 Wall Street analysts forecast DXCM's revenue for 2027 to be $2,293,243,102,311, with the lowest DXCM revenue forecast at $2,154,328,830,591, and the highest DXCM revenue forecast at $2,431,771,501,054.
In 2028, DXCM is forecast to generate $2,556,794,345,602 in revenue, with the lowest revenue forecast at $2,340,319,605,505 and the highest revenue forecast at $2,821,889,080,801.